0.0000 (0.0000%)
  • Bid / Lots
    0.2810/ 17
  • Ask / Lots
    0.3040/ 1
  • Open / Previous Close
    0.0000 / 0.2859
  • Day Range
  • 52 Week Range
    Low 0.2280
    High 2.0700
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.288
09:32 ET41640.293
09:34 ET15000.288101
09:36 ET27570.291
09:38 ET1000.2921
09:39 ET4000.2909
09:41 ET101420.288
09:43 ET8940.2902
10:14 ET20000.29
10:21 ET1100.29
10:24 ET20000.29
10:26 ET10000.29
10:37 ET10000.288
10:42 ET20000.29
10:51 ET1010.2889
11:00 ET5040.2899
11:04 ET1252030.290801
11:08 ET40000.2908
11:33 ET25340.2908
11:38 ET2680.294551
11:49 ET600000.2908
12:05 ET190000.2901
12:12 ET34960.2877
12:18 ET2000.2892
12:20 ET1500.286
12:27 ET11000.286
12:30 ET3500.285
12:36 ET209840.288
12:38 ET285500.2834
12:39 ET10000.2834
12:59 ET35000.2871
01:01 ET1000.2872
01:06 ET51000.29
01:08 ET66000.29
01:10 ET570990.29
01:12 ET4000.2947
01:17 ET2500.294
01:19 ET2000.2901
01:28 ET1000.2979
01:53 ET35000.2915
02:11 ET4000.2914
02:31 ET80000.291199
03:02 ET200000.2854
03:25 ET51000.29
03:27 ET30090.287998
03:30 ET9890.2882
03:32 ET46010.2899
03:34 ET22800.2899
03:56 ET17000.2859
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSONN
Sonnet Biotherapeutics Holdings Inc
United StatesLEXX
Lexaria Bioscience Corp
United StatesEDXC
Endexx Corp
United StatesHOTH
Hoth Therapeutics Inc
United StatesCYTH
Cyclo Therapeutics Inc
United StatesNLBS
Nutralife Biosciences Inc
As of 2022-08-10

Company Information

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company’s technology, namely fully human albumin binding (FHAB) helps to develop biologic medicines. FHAB utilizes a fully human single chain antibody fragment linked to either one or two therapeutic molecules capable of affecting single or bispecific mechanisms of action. The FHAB construct contains a domain, which is designed to bind to and hitch hike on human serum albumin for transport to targets, such as solid tumors or to the lymphatic system. It designed the construct to improve drug accumulation in specific tissues, as well as to extend the duration of activity in the body. FHAB development candidates are produced in a mammalian cell culture, which enables glycosylation, thereby reducing the risk of immunogenicity. FHAB technology can help in drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory and hematological conditions.

Contact Information

100 Overlook Center, Suite 102PRINCETON, NJ, United States 08540


Chairman of the Board, President, Chief Executive Officer
Pankaj Mohan
Chief Financial Officer
John Cross
Chief Scientific Officer
John Cini
Chief Technical Officer
Susan Dexter
Chief Medical Officer
Richard Kenney

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.